Asuragen
Latest round
- Series C
Last raised
- Mar 2013
Total raised
- $80M
Investors
- 4
About Asuragen
Asuragen Inc.Founded in 2005 in Austin, US, Asuragen Inc. focuses on molecular diagnostics and genetics, offering innovative solutions in the healthcare sector. The company has undergone strategic developments, including a partial acquisition by Interpace Diagnostics Group in August 2014, which has influenced its operational focus. Growth Capital Fund and PTV Healthcare Capital.Asuragen, Inc. specializes in molecular diagnostics, genetics, and oncology testing kits aimed at addressing complex genetic disorders and cancers. Their core product offerings include the AmplideX® brand, which encompasses a range of genetic analysis solutions for carrier screening research, such as the AmplideX® Nanopore Carrier Plus Kit, and diagnostic tests like the QuantideX® qPCR BCR-ABL IS Kit, which monitors chronic myeloid leukemia (CML). These products are designed for use in clinical laboratories and are optimized for established laboratory equipment, enabling the detection of various genetic mutations associated with conditions such as fragile X syndrome, Huntington’s disease, and cystic fibrosis. Asuragen’s customer base includes clinical laboratories, research institutions, and healthcare providers across the EMEA region, particularly focusing on European markets where compliance with local diagnostic regulations is a priority.Asuragen generates revenue through direct sales of its molecular diagnostics and testing kits, primarily operating on a B2B model with clinical laboratories and healthcare institutions as primary clients. The company structures its transactions around the provision of testing kits, reagents, and accompanying analysis software, facilitating laboratory testing processes. Their flagship products, like the AmplideX® Nanopore Carrier Plus Kit and the QuantideX® qPCR kits, represent significant offerings within the molecular diagnostics sector, contributing to the company’s revenue streams. Pricing strategies are designed to reflect the advanced technology and comprehensive support services provided, ensuring that clients receive reliable, high-quality diagnostic tools tailored to their specific needs. The company is currently developing new testing kits aimed at improving genetic diagnosis, with anticipated launches in the upcoming years. Additionally, Asuragen is targeting expansion into new geographic regions, particularly within the European market, to capitalize on growing demands for genetic testing solutions.
Who invested in Asuragen
4 investors across 4 rounds
See all investors in Asuragen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Asuragen
Who invested in Asuragen?
Asuragen has 4 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Asuragen raised?
Asuragen has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Asuragen last raise money?
Asuragen's most recent round on record is a Series C, in Mar 2013.
What does Asuragen do?
Asuragen is a biotechnology company.
Where is Asuragen headquartered?
Asuragen is headquartered in Austin, US.
Which VCs invest in companies like Asuragen?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Asuragen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Asuragen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.